HILS vs. NBTX, SKYE, ANRO, SBTX, URGN, AVIR, QTTB, KMDA, XOMA, and LLY
Should you be buying Hillstream BioPharma stock or one of its competitors? The main competitors of Hillstream BioPharma include Nanobiotix (NBTX), Skye Bioscience (SKYE), Alto Neuroscience (ANRO), Silverback Therapeutics (SBTX), UroGen Pharma (URGN), Atea Pharmaceuticals (AVIR), Q32 Bio (QTTB), Kamada (KMDA), XOMA (XOMA), and Eli Lilly and Company (LLY). These companies are all part of the "pharmaceutical preparations" industry.
Nanobiotix (NASDAQ:NBTX) and Hillstream BioPharma (NASDAQ:HILS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.
38.8% of Nanobiotix shares are held by institutional investors. Comparatively, 13.4% of Hillstream BioPharma shares are held by institutional investors. 3.5% of Nanobiotix shares are held by company insiders. Comparatively, 30.2% of Hillstream BioPharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Hillstream BioPharma has lower revenue, but higher earnings than Nanobiotix.
Nanobiotix has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500. Comparatively, Hillstream BioPharma has a beta of 3.08, suggesting that its stock price is 208% more volatile than the S&P 500.
Hillstream BioPharma's return on equity of 0.00% beat Nanobiotix's return on equity.
Nanobiotix currently has a consensus target price of $11.00, indicating a potential upside of 56.25%. Given Hillstream BioPharma's stronger consensus rating and higher possible upside, research analysts clearly believe Nanobiotix is more favorable than Hillstream BioPharma.
Nanobiotix received 9 more outperform votes than Hillstream BioPharma when rated by MarketBeat users. Likewise, 62.50% of users gave Nanobiotix an outperform vote while only 50.00% of users gave Hillstream BioPharma an outperform vote.
In the previous week, Nanobiotix had 2 more articles in the media than Hillstream BioPharma. MarketBeat recorded 3 mentions for Nanobiotix and 1 mentions for Hillstream BioPharma. Nanobiotix's average media sentiment score of 0.67 beat Hillstream BioPharma's score of 0.18 indicating that Hillstream BioPharma is being referred to more favorably in the news media.
Summary
Nanobiotix beats Hillstream BioPharma on 10 of the 14 factors compared between the two stocks.
Get Hillstream BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for HILS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HILS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hillstream BioPharma Competitors List
Related Companies and Tools
